Comparative efficacy of HPV 16/18 DNA and E6/E7 mRNA testing in detecting high-grade cervical lesions (CIN2+) in women with cervical biopsies
- PMID: 39733635
- DOI: 10.1016/j.diagmicrobio.2024.116668
Comparative efficacy of HPV 16/18 DNA and E6/E7 mRNA testing in detecting high-grade cervical lesions (CIN2+) in women with cervical biopsies
Abstract
The study evaluated the efficacy of HPV 16/18 E6/E7 mRNA detection in women with abnormal cervical histology. A total of 99 cervical biopsy samples were analyzed, including 49 benign, 16 with cervical intraepithelial neoplasia grade 1 (CIN1), 9 with CIN2/3, and 25 with cervical cancers. Samples were tested for HPV 16/18 using both DNA and mRNA RT-PCR methods. The findings revealed a sensitivity of 85.3 % (29/34) for the HPV DNA test and 76.5 % (26/34) for the mRNA test in detecting CIN2+ lesions. Notably, the E6/E7 mRNA test demonstrated greater specificity for CIN2+ at 75.4 % (49/65), compared to 52.3 % (34/65) for the DNA test. The prevalence of positive results for both tests increased with the severity of squamous cell abnormalities. However, the HPV 16/18 E6/E7 mRNA test provided superior specificity, making it a more effective method for cervical cancer screening in this region, offering more precise results than DNA testing alone.
Keywords: Cervical cancer; E6/E7 mRNA; HPV 16/18; Real-Time PCR.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hamid Sadeghi reports financial support was provided by Qazvin University of Medical Sciences. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.J Med Virol. 2013 Jun;85(6):1063-8. doi: 10.1002/jmv.23544. J Med Virol. 2013. PMID: 23588733
-
Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.J Clin Microbiol. 2009 Dec;47(12):3895-901. doi: 10.1128/JCM.01275-09. Epub 2009 Oct 14. J Clin Microbiol. 2009. PMID: 19828739 Free PMC article.
-
Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.Clin Lab. 2018 Sep 1;64(9):1363-1371. doi: 10.7754/Clin.Lab.2018.180138. Clin Lab. 2018. PMID: 30274003
-
The clinical application of HPV E6/E7 mRNA testing in triaging women with atypical squamous cells of undetermined significance or low-grade squamous intra-epithelial lesion Pap smear: A meta-analysis.J Cancer Res Ther. 2017;13(4):613-620. doi: 10.4103/jcrt.JCRT_56_17. J Cancer Res Ther. 2017. PMID: 28901302 Review.
-
Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta-analysis.J Med Virol. 2023 Jan;95(1):e27900. doi: 10.1002/jmv.27900. Epub 2022 Jun 9. J Med Virol. 2023. PMID: 35641882 Free PMC article.
Cited by
-
Comparison of Diagnostic Methods in Patients with Squamous Intraepithelial Lesion in Women Infected with Multiple High-Risk Human Papillomaviruses.Iran J Pathol. 2025;20(1):108-117. doi: 10.30699/ijp.2024.2036312.3330. Epub 2025 Jan 10. Iran J Pathol. 2025. PMID: 40060225 Free PMC article.
-
High-risk HPV genotypes in women with abnormal cytology: a 12-year retrospective study.Infect Agent Cancer. 2025 May 26;20(1):34. doi: 10.1186/s13027-025-00664-0. Infect Agent Cancer. 2025. PMID: 40414896 Free PMC article.